Affordable Access

deepdyve-link
Publisher Website

Collagen XI alpha 1 chain, a potential therapeutic target for cancer.

Authors
  • Liu, Ziqiang1
  • Lai, Jiacheng1
  • Jiang, Heng1
  • Ma, Chengyuan1
  • Huang, Haiyan1
  • 1 Department of Neurosurgery, the First Hospital of Jilin University, Changchun, China. , (China)
Type
Published Article
Journal
The FASEB Journal
Publisher
Federation of American Society for Experimental Biology
Publication Date
Jun 01, 2021
Volume
35
Issue
6
Identifiers
DOI: 10.1096/fj.202100054RR
PMID: 33999448
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and it is involved in the biological formation of cancer. Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) has been found to be upregulated in a variety of cancers including ovarian cancer, breast cancer, thyroid cancer, pancreatic cancer, non-small-cell lung cancer, and transitional cell carcinoma of the bladder. High levels of COL11A1 usually predict poor prognosis, while COL11A1 is related to angiogenesis, invasion, and drug resistance of cancer. However, little is known about the specific mechanism by which COL11A1 regulates tumor progression. Here, we have organized and summarized the recent developments regarding elucidation of the relationship between COL11A1 and various cancers, as well as the interaction between COL11A1 and intracellular signaling pathways. In addition, we have selected therapeutic agents targeting COL11A1. All these indicate the possibility of using COL11A1 as a target for cancer treatment. © 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Report this publication

Statistics

Seen <100 times